A detailed history of Rbf Capital, LLC transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Rbf Capital, LLC holds 140,000 shares of ADGI stock, worth $463,400. This represents 0.03% of its overall portfolio holdings.

Number of Shares
140,000
Previous 150,000 6.67%
Holding current value
$463,400
Previous $496,000 6.65%
% of portfolio
0.03%
Previous 0.03%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
N/A
-10,000 Reduced 6.67%
140,000 $463,000
Q4 2023

Feb 14, 2024

SELL
N/A
-53,683 Reduced 26.36%
150,000 $496,000
Q2 2023

Aug 14, 2023

BUY
N/A
203,683 New
203,683 $674,000

Others Institutions Holding ADGI

About Adagio Therapeutics, Inc.


  • Ticker ADGI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 108,831,000
  • Market Cap $505M
  • Description
  • Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...
More about ADGI
Track This Portfolio

Track Rbf Capital, LLC Portfolio

Follow Rbf Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rbf Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rbf Capital, LLC with notifications on news.